Oncology Care Included in Medicare Disease Management Demonstrations

Publication
Article
OncologyONCOLOGY Vol 16 No 6
Volume 16
Issue 6

Oncology care will be the focus of one of the new Medicare disease management demonstration programs soon to be initiated. Medicare remains convinced that disease management services can provide substantial savings. There is, however, a problem: Fee-for-service Medicare, which includes most recipients, does not allow for disease management, except in one or two instances, such as diabetes self-education. The Medicare+Choice program-comprised mostly of health maintenance organizations-offers disease management, but seniors have, for the most part, avoided this plan. Therefore, Medicare has selected 15 sites for case management and disease management services, which will be offered to Medicare fee-for-service beneficiaries with complex chronic conditions. Quality Oncology, Inc, of McLean, Va, will implement an urban disease management program targeting beneficiaries in Broward County, Fla.

Oncology care will be the focus of one of the newMedicare disease management demonstration programs soon to be initiated.Medicare remains convinced that disease management services can provide substantialsavings. There is, however, a problem: Fee-for-service Medicare,which includes most recipients, does not allow for disease management, except inone or two instances, such as diabetes self-education. The Medicare+Choiceprogram—comprised mostly of health maintenance organizations—offers diseasemanagement, but seniors have, for the most part, avoided this plan. Therefore,Medicare has selected 15 sites for case management and disease managementservices, which will be offered to Medicare fee-for-service beneficiaries withcomplex chronic conditions. Quality Oncology, Inc, of McLean, Va, will implementan urban disease management program targeting beneficiaries in Broward County,Fla. 

The idea is for Quality Oncology to match the plan of care written by thepatient’s own oncologist. The Quality program’s medical director willcontact the patient’s oncologist to discuss any differences between the careplan and the guidelines. A care manager will provide patient education andcounseling, care coordination, and service arrangement.

Recent Videos
Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Leadership of a new cancer center as part of JFK University Medical Center discuss how they can support frontline clinicians.
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
Related Content